InvestorsHub Logo
Followers 10
Posts 569
Boards Moderated 1
Alias Born 02/12/2021

Re: MelsDollars post# 41022

Thursday, 07/22/2021 2:40:23 PM

Thursday, July 22, 2021 2:40:23 PM

Post# of 44690
Thanks Mel... GREAT INFORMATION !!!

Its know by most longs, but the FUDsters like to try and instill FUD even when the truth is out there. Great Reminder........


Relief owns U.S. Patent No. 8,178,489, related Patents derived from U.S. Patent Application Serial No. 11/817,867 and foreign formulation patents, which are being utilized under the Collaboration agreement with NeuroRx. Under the collaboration agreement, all potential new IP obtained by either Relief or NeuroRx related to aviptadil is required to be cross-licensed between the parties.


The binding collaboration agreement between Relief Therapeutics and NeuroRx entered into in September 2020 remains in full force and effect. Relief believes that it is in compliance with the collaboration agreement and that there are no grounds for renegotiating the profit sharing arrangements contained in the collaboration agreement. According to the agreement, Relief is entitled to 50% of the net profits from the sales in the NeuroRx territory, which includes the U.S., Canada and Israel.

My opinion is reflected in my posts, and it is never advice to buy, sell or trade any securities. Do your own due diligence before purchasing anything in the stock market.